Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
Metastatic Melanoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 220 (final count)
- Started
- Sep 24, 2015
- Main results expected
- Oct 24, 2024
- Fully finished
- Oct 24, 2024
- Results posted
- Dec 9, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Disease Assessment for Objective Response Rate
Measured over: Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02360579 · record last updated 2026-03-25 · checked 2026-11-09 15:47 UTC